All In Biotech

NDA 205580 · Eagle Pharms

Belrapzo

Bendamustine Hydrochloride · Intravenous

Orphan

Last checked: Nov 20, 2026Latest source record: Jan 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 15, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

426

81 Phase 3, 51 recruiting

FAERS reports

7,960

7,615 serious, 1,555 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 15, 2018 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • BELRAPZO · BENDAMUSTINE HYDROCHLORIDE 100MG/4ML (25MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use996
  • pyrexia555
  • disease progression511
  • covid-19406
  • product use in unapproved indication400
  • drug ineffective392
  • febrile neutropenia366
  • malignant neoplasm progression362
  • neutrophil count decreased354
  • neutropenia344
  • platelet count decreased342
  • pneumonia341

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20093
20102
201115
2012129
201346
2014267
2015423
2016435
2017400
2018594
2019583
2020608
2021732
20221,446
20231,014
2024736
2025295
2026231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Belrapzo* (Bendamustine HCL*) · HCPCS J9036

2024 spending

$4.6M

Beneficiaries

495

2,377 claims

Per beneficiary

$9,283

2024 ASP limit $10.22 per unit

View as table
YearSpending
2020$12,566,160
2021$12,048,142
2022$15,568,129
2023$11,585,396
2024$4,595,288

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 385 on PubMed

Sponsor: Eagle Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.